SYSTEMIX REPORTS HIV FINDING IN 'NATURE'
PALO ALTO, Calif., June 24 /PRNewswire/ -- SyStemix, Inc. (NASDAQ: STMX) announced the publication of an article, titled "HIV Induces Thymus Depletion In Vivo," appearing today in the July edition of the scientific journal, Nature. SyStemix' scientists showed in the SCID-hu mouse model that HIV can destroy developing T cells in the human thymus. T cells are important in fighting viral infections and are among the cells most vulnerable to HIV infection. The experiments also indicated that HIV destroys the immune systems' ability to generate new T cells and thus the virus does not allow for the regeneration of an otherwise destroyed circulating T cell pool. These findings are important steps forward in understanding the ways in which HIV causes disease and therefore developing effective therapies. SyStemix proprietary SCID-hu mouse is the only animal model available to study HIV infection in the setting of human organs. The animal model is constructed by implanting fragments of human organs into the immunodeficient SCID mouse. SyStemix' scientists demonstrated, in this most recent study, that the SCID-hu mouse not only serves to validate known observations about the human immune system but can also be used to uncover previously undefined mechanisms by which HIV compromises the immune system. "The publication of this article validates SyStemix' approach to the development of viable therapies to treat infection and prevent replication of the AIDS virus," said Linda Sonntag, Ph.D., president and CEO of SyStemix. "We are currently using the SCID-hu mouse to study chemotherapies for AIDS, gene therapy of AIDS and cellular therapies as adjuncts for cancer chemotherapy." The authors of the paper are Mark Bonyhadi, Ph.D., Linda Rabin, M.S., Suzan Salimi, M.S., Joseph M. McCune, M.D., Ph.D. and Hideto Kaneshima, M.D., Ph.D. from SyStemix as well as Daniel Brown, M.A., and Jon Kosek, M.D., from the Veterans Administration Hospital of Palo Alto. SyStemix, Inc. based in Palo Alto, is primarily engaged in the development of cellular processes and products based on human hematopoietic stem cells, human megakaryocytes and megkaryocyte progenitors. -0- 6/24/93 /CONTACT: Linda Sonntag, Ph.D., president and CEO of SyStemix, Inc. 415-813-6510, or Anthony J. Russo, Ph.D., of Noonan Russo Communications Inc., 212-979-9180/
CO: SyStemix, Inc. ST: California IN: MTC SU:
LR-SM -- NY012 -- 5201 06/24/93 09:42 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 24, 1993|
|Previous Article:||VITAL HEART SYSTEMS, INC. ANNOUNCES VERY SUCCESSFUL LAUNCH OF VITAL HEART CHECKPOINT CENTERS|
|Next Article:||MITCHELL REPORTS FOUR LIMESTONE COUNTY PRODUCERS|